MicroPort

On February 27, announced that its First-in-Class ™ Piezoelectric Coronary CTO Crossing Guidewire has received official approval from the National Medical Products Administration ( ) of China through the Innovative Medical Device Special Review ("Green Channel") program.

🚀 Product Highlights:
The system converts electrical energy into precisely controlled high-frequency mechanical vibrations, transmitted along the guidewire shaft to its distal tip, enabling targeted antegrade mechanical impulses to facilitate CTO lesion pe*******on and micro-channel creation.

1️⃣ Enhanced Pe*******on of Complex CTO Lesions: Effectively addresses resistant fibrotic proximal caps and heavily calcified occlusions that may be refractory to conventional guidewires.

2️⃣ Improved Revascularization Success: Lesion-targeted mechanical energy delivery supports successful recanalization and restoration of coronary blood flow across a broader CTO patient population.

3️⃣ Reduced Procedural Risk and Optimized Efficiency: Controlled lesion crossing may reduce wire escalation, shorten procedure time, and lower potential intra-procedural risks, thereby enhancing overall treatment safety.

The approval of FireSpear™ marks a significant milestone in our commitment to advancing coronary artery disease treatment, showcasing our strong R&D capabilities and ability to translate cutting-edge engineering into clinically meaningful innovation. Looking ahead, we aim to enable more patients worldwide to live .

underscores a strategic advancement as its coronary product portfolio achieves institutional access and enters routine clinical use at a leading hospital in Macao, China. The portfolio covers key interventional segments including stents, balloons, and CTO accessory, marking an important step in the company's systematic regional expansion and providing valuable clinical reference for the broader Asia-Pacific market.

Products now in clinical application include Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System, Firesorb™ Bioresorbable Rapamycin Eluting Coronary Scaffold System, Firefighter™ / Firefighter™ NC PTCA Balloon Dilatation Catheter, and Fireflow™ MicroCross™ Microcatheter.

Macao's highly internationalized healthcare system applies rigorous standards to the adoption of interventional devices. Clinical experience generated in this market is expected to provide valuable reference for regional and global practice.

We remain committed to advancing innovative solutions for the management of complex coronary diseases. Building on the successful, system-level clinical adoption of its coronary portfolio in Macao, we will continue to expand clinical collaboration, accelerate regional and global access, and deliver advanced, reliable coronary therapies in support of for patients worldwide.